Literature DB >> 24178909

Regulation of onco and tumor suppressor MiRNAs by mTORC1 inhibitor PRP-1 in human chondrosarcoma.

Karina A Galoian1, Toumy Guettouche, Biju Issac, Amir Qureshi, H T Temple.   

Abstract

Metastatic chondrosarcoma of mesenchymal origin is the second most common bone malignancy and does not respond either to chemotherapy or radiation; therefore, the search for new therapies is relevant and urgent. This study aimed to reveal the comparative analysis of miRNAs and their targets in human JJ012 chondrosarcoma cell line between control and experimental samples, treated with mTORC1 inhibitor, cytostatic antiproliferative proline-rich polypeptide (PRP-1). Examination of tumor-specific microRNA expression profiles has revealed widespread deregulation of these molecules in diverse cancers. It was reported that microRNAs can function as novel biomarkers for disease diagnostics and therapy, as well as a novel class of oncogenes and tumor suppressor genes. mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24178909     DOI: 10.1007/s13277-013-1309-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  39 in total

1.  Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo.

Authors:  Takashi Kobayashi; Takahiro Inoue; Yosuke Shimizu; Naoki Terada; Atsushi Maeno; Yoichiro Kajita; Toshinari Yamasaki; Tomomi Kamba; Yoshinobu Toda; Yoshiki Mikami; Tomomi Yamada; Toshiyuki Kamoto; Osamu Ogawa; Eijiro Nakamura
Journal:  Mol Endocrinol       Date:  2010-03-04

2.  Integrated profiling of diffuse large B-cell lymphoma with 7q gain.

Authors:  Ekaterina Chigrinova; Michael Mian; Yulei Shen; Timothy C Greiner; Wing C Chan; Julie M Vose; Giorgio Inghirami; Annalisa Chiappella; Luca Baldini; Maurilio Ponzoni; Andrés J M Ferreri; Silvia Franceschetti; Gianluca Gaidano; Alessandra Tucci; Fabio Facchetti; Thierry Lazure; Olivier Lambotte; Santiago Montes-Moreno; Miguel A Piris; Emanuele Zucca; Ivo Kwee; Francesco Bertoni
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

3.  mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.

Authors:  Karina Galoian; H T Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2012-01-14

4.  A new hypothalamic polypeptide is a regulator of myelopoiesis.

Authors:  Armen A Galoyan; Vardan S Aprikyan
Journal:  Neurochem Res       Date:  2002-04       Impact factor: 3.996

5.  MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.

Authors:  C Oneyama; J Ikeda; D Okuzaki; K Suzuki; T Kanou; Y Shintani; E Morii; M Okumura; K Aozasa; M Okada
Journal:  Oncogene       Date:  2011-03-07       Impact factor: 9.867

6.  Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215.

Authors:  Sara A Georges; Matthew C Biery; Soo-Yeon Kim; Janell M Schelter; Jane Guo; Aaron N Chang; Aimee L Jackson; Michael O Carleton; Peter S Linsley; Michele A Cleary; B Nelson Chau
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.

Authors:  Yvonne M Schrage; Inge H Briaire-de Bruijn; Noel F C C de Miranda; Jolieke van Oosterwijk; Antonie H M Taminiau; Tom van Wezel; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

8.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

9.  A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer.

Authors:  Hua Zhao; Jie Shen; Leonard Medico; Dan Wang; Christine B Ambrosone; Song Liu
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  Antitumorigenic effect of brain proline rich polypeptide-1 in human chondrosarcoma.

Authors:  Karina Galoian; Sean Scully; George McNamara; Patrick Flynn; Armen Galoyan
Journal:  Neurochem Res       Date:  2009-12       Impact factor: 3.996

View more
  13 in total

1.  Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma.

Authors:  Karina Galoian; Shihua Luo; Amir Qureshi; Parthik Patel; Rachel Price; Ashlyn S Morse; Gor Chailyan; Silva Abrahamyan; H T Temple
Journal:  Mol Clin Oncol       Date:  2016-09-02

2.  Epigenetic control of cancer by neuropeptides.

Authors:  Karina Galoian; Parthik Patel
Journal:  Biomed Rep       Date:  2016-11-08

3.  MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2.

Authors:  Jun Cao; Yang He; Hong-Qiang Liu; Sai-Bo Wang; Bao-Cheng Zhao; Ying-Sheng Cheng
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 4.  MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics.

Authors:  Jyotika Varshney; Subbaya Subramanian
Journal:  Front Mol Biosci       Date:  2015-06-17

5.  Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1.

Authors:  Karina Galoian; Amir Qureshi; Gianluca D'Ippolito; Paul C Schiller; Marco Molinari; Andrea L Johnstone; Shaun P Brothers; Ana C Paz; H T Temple
Journal:  Int J Oncol       Date:  2015-06-18       Impact factor: 5.650

6.  No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Authors:  Elisabeth F P Peterse; Arjen H G Cleven; Yvonne De Jong; Inge Briaire-de Bruijn; Jonathan A Fletcher; Erik H J Danen; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  BMC Cancer       Date:  2016-07-14       Impact factor: 4.430

7.  Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma.

Authors:  Karina Galoian; Silva Abrahamyan; Gor Chailyan; Amir Qureshi; Parthik Patel; Gil Metser; Alexandra Moran; Inesa Sahakyan; Narine Tumasyan; Albert Lee; Tigran Davtyan; Samvel Chailyan; Armen Galoyan
Journal:  Int J Oncol       Date:  2017-11-09       Impact factor: 5.650

Review 8.  MicroRNA function and dysregulation in bone tumors: the evidence to date.

Authors:  Mary Nugent
Journal:  Cancer Manag Res       Date:  2014-01-07       Impact factor: 3.989

9.  CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells.

Authors:  Guan-Ting Liu; Hsien-Te Chen; Hsi-Kai Tsou; Tzu-Wei Tan; Yi-Chin Fong; Po-Chen Chen; Wei-Hung Yang; Shih-Wei Wang; Jui-Chieh Chen; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2014-11-15

10.  Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma.

Authors:  Xing Bao; Tingting Ren; Yi Huang; Shidong Wang; Fan Zhang; Kuisheng Liu; Bingxin Zheng; Wei Guo
Journal:  J Exp Clin Cancer Res       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.